Omega-3 fatty acids: Their role in the prevention and treatment of atherosclerosis related risk factors and complications

International Journal of Clinical Practice

Volumn 57, Issue 4, 2003, Pages 305-314

  Bhatnagar, D ^a   Durrington, P N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BLOOD CLOTTING FACTOR; DIOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYCHLORINATED BIPHENYL; POLYUNSATURATED FATTY ACID; PRAVASTATIN; RETINOL; SIMVASTATIN; TRIACYLGLYCEROL; VITAMIN D;

ARTICLE; ATHEROSCLEROSIS; BLEEDING TENDENCY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DYSLIPOPROTEINEMIA; DYSPEPSIA; ENERGY RESOURCE; ERUCTATION; FATTY ACID METABOLISM; FISH; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEARTBURN; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MONOTHERAPY; MUTAGENICITY; NAUSEA; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SECONDARY PREVENTION; SUDDEN DEATH; THROMBOCYTE FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; VEGETABLE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DEATH, SUDDEN, CARDIAC; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FOOD HABITS; GENE EXPRESSION; HEMOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0038541575     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. Ahrens EH, Insull W, Hirsch. J et al. The effect on human serum lipids of a dietary fat highly unsaturated, but poor in essential fatty acids. Lancet, 1959; i: 115-119.
2. Kingsbury KJ, Morgan DM, Aylott C, Emmerson R. Effcets of ethyl arachidonate, cod liver oil and corn oil on the plasma cholesterol level. Lancet 1961; i: 739.
3. Krauss RM, Eckel RH, Howard B et al. AHA dietary guidelines: revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 2284-2299.
4. Troisi R, Willett WC, Weiss ST. Trans-fatty acid intake in relation to serum lipid concentrations in adult men. Am J Clin Nutr 1992; 56: 1019-1024.
5. Keys A, Anderson JT, Grande F. Serum cholesterol response to dietary fat. Lancet 1957; i: 787.
6. Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr 1997; 66(suppl): 1020S-1031S.
7. Roche HM, Gibney MJ. Postprandial triacylglycerolaemia: the effect of low-fat dietary treatment with and without fish oil supplementation. Eur J Clin Nutr 1996; 50: 617-624.
8. Durrington PN. Hyperlipidaemia: diagnosis and management, 2nd edn. Oxford: Butterworth Heinemann, 1995.
9. Simopoulos AP, Leaf A, Salem N Jr. Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab 1999; 43: 127-30.
10. McLennan PL, Abeywardena MY, Charnock JS. Influence of dietary lipids on arrhythmias and infarction after coronary artery ligation in rats. Can J Physiol Pharmacol 1985; 63: 1411-1417.
11. Appel LJ, Miller ER III, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993; 153: 1429-1438.
12. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446-2450.
13. Barcelli U, Glas-Greenwalt P, Pollak VE. Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res Suppl.1985; 39: 307-312.
14. Meydani SN, Lichtenstein AH, Cornwall S et al. Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J Clin Invest 1993; 92: 105-113.
15. Lee TH, Hoover RL, Williams JD et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 312: 1217-1224.
16. Bhatnagar D. Hypertriglyceridaemia. In: Betteridge DJ, Illingworth DR Shepherd J, Eds. Lipoproteins in health and disease. London: Edward Arnold, 1999.
17. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
18. Sinclair HM. Deficiency of essential fatty acids and atherosclerosis. Lancet 1978; ii: 117-119.
19. Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand 1976; 200: 69-73.
20. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 1980; 208: 401-406.
21. Marckmann P, Gronbaek M. Fish consumption and coronary heart disease mortality: a systematic review of prospective cohort studies. Eur J Clin Nutr 1999; 53: 585-590.
22. Albert CM, Hennekens CM, O'Donnell CJ et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28.
23. Ascherio A, Rimm EB, Stampfer MJ et al. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995; 332: 977-982.
24. Oomen CM, Feskens EJ, Rasanen L et al. Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol 2000; 151: 999-1006.
25. Simonsen T, Vartun A, Lyngmo V, Nordoy A. Coronary heart disease, serum lipids, platelets and dietary fish in two communities in northern Norway. Acta Med Scand 1987; 222: 237-245.
26. Rissanen T, Voutilainen S, Nyyssonen K et al. Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. Circulation 2000; 102: 2677-2679.
27. Albert CM, Campos H, Stampfer MJ et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002; 346: 1113-1118.
28. Guallar E, Hennekens CH, Sacks FM et al. A prospective study of plasma fish oil levels and incidence of myocardial infarction in US male physicians. J Am Coll Cardiol 1995; 25: 387-394.
29. Hu FB, Bronner L, Willett WC et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-1821.
30. Curb JD, Reed DM. Fish consumption and mortality from coronary heart disease. N Engl J Med 1985; 313: 821-822.
31. Hu FB, Stampfer MJ, Manson JE et al. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. Am J Clin Nutr 1999; 69: 890-897.
32. Guallar E, Aro A, Jimenez FJ et al. Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC study. Arterioscler Thromb Vasc Biol 1999; 19: 1111-1118.
33. Oomen CM, Ocke MC, Feskens EJ et al. Alpha-linolenic acid intake is not beneficially associated with 10-y risk of coronary artery disease incidence: the Zutphen Elderly Study. Am J Clin Nutr 2001; 74: 457-463.
34. de Lorgeril M, Renaud S, Mamelle N et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-1459.
35. Sacks FM, Stone PH, Gibson CM et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995; 25: 1492-1498.
36. von Schacky C, Angerer P, Kothny W et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130: 554-562.
37. Johansen O, Brekke M, Seljeflot I et al. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J Am Coll Cardiol 1999; 33: 1619-1626.
38. Eritsland J, Arnesen H, Gronseth K et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77: 31-36.
39. Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; ii: 757-761.
40. Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction. Eur Heart J 1994; 15: 1152-1153.
41. de Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.
42. GISSI-Prevention Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevention trial. Lancet 1999; 354: 447-455.
43. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903.
44. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
45. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study, a randomized controlled trial. JAMA 2001; 285: 1711-1718.
46. Harris WS, Isley WL. Clinical trial evidence for the cardioprotective effects of omega 3 fatty acids. Curr Atheroscler Rep 2001; 3: 174-179.
47. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
48. Anon. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
49. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
50. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
51. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
52. Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001; 104: 756-761.
53. Siscovick DS, Raghunathan TE, King I et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363-1367.
54. Leaf A. Plasma nonesterified fatty acid concentration as a risk factor for sudden cardiac death. The Paris Prospective Study. Circulation 2001; 104: 744-745.
55. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 1995; 76: 974-977.
56. Landmark K, Abdelnoor M, Urdal P et al. Use of fish oils appears to reduce infarct size as estimated from peak creatine kinase and lactate dehydrogenase activities. Cardiology 1998; 89: 94-102.
57. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999; 99: 2452-2457.
58. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 1994; 91: 9886-9890.
59. Kang JX, Leaf A. Prevention and termination of beta-adrenergic agonist-induced arrhythmias by free polyunsaturated fatty acids in neonatal rat cardiac myocytes. Biochem Biophys Res Commun 1995; 208: 629-636.
60. Leaf A, Kang JX. Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. J Intern Med 1996; 240: 5-12.
61. Kang JX, Xiao YF, Leaf A. Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 1995; 92: 3997-4001.
62. Xiao YF, Wright SN, Wang GK et al. Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc Natl Acad Sci USA 1998; 95: 2680-2685.
63. Christensen JH, Skou HA, Fog L et al. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation 2001; 103: 651-657.
64. Christensen JH, Korup E, Aaroe J et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997; 79: 1670-1673.
65. Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 1999; 70: 331-337.
66. Christensen JH, Toft E, Christensen MS, Schmidt EB. Heart rate variability and plasma lipids in men with and without ischaemic heart disease. Atherosclerosis 1999; 145: 181-186.
67. Kleiger RE, Miller JP, Bigger JT et al. Decreased heart rate variability and its association with increased mortality after acute acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
68. Christensen JH, Gustenhoff P, Korup E et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 1996; 312: 677-678.
69. Christensen JH, Aaroe J, Knudsen N et al. Heart rate variability and n-3 fatty acids in patients with chronic renal failure: a pilot study. Clin Nephrol 1998; 49: 102-106.
70. Cook JR, Bigger JT Jr, Kleiger RE et al. Effect of atenolol and diltiazem on heart period variability in normal persons. J Am Coll Cardiol 1991; 17: 480-484.
71. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids. Nutr Metab Cardiovasc Dis 2000; 10: 28-37.
72. Harris WS. Omega-3 long-chain fatty PUFA and triglyceride lowering: minimum effective intakes. Eur Heart J 2001; 3(suppl D): D59-D61.
73. Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 1992; 27: 533-538.
74. Westphal S, Orth M, Ambrosch A et al. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr 2000; 71: 914-920.
75. Dagnelie PC, Rietveld T, Swart GR et al. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans. Lipids 1994; 29: 41-45.
76. Hsu HC, Lee YT, Chen MF. Effect of n-3 fatty acids on the composition and binding properties of lipoproteins in hypertriglyceridemic patients. Am J Clin Nutr 2000; 71: 28-35.
77. Bordin P, Bodamer OA, Venkatesan et al. Effects of fish oil supplementation on apolioprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur J Clin Nutr 1998; 52: 104-109.
78. Kasim-Karakas SE, Herrmann R, Almario R. Effects of omega-3 fatty acids on intravascular lipolysis of very-low-density lipoproteins in humans. Metabolism 1995; 44: 1223-1230.
79. Pownall HJ, Brauchi D, Kilinc C et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999; 143: 285-297.
80. Minihane AM, Khan S, Leigh-Firbank EC et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000; 20: 1990-1997.
81. Mori TA, Burke V, Puddey IB et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-1094.
82. Rambjor GS, Walen AI, Windsor SL, Harris WS. Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids 1996; 31(suppl): S45-S49.
83. Bonaa KH, Bjerve KS, Straume B et al. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromso study. N Engl J Med 1990; 322: 795-801.
84. Kestin M, Clifton P, Belling GB, Nestel PJ. n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. Am J Clin Nutr 1990; 51: 1028-1034.
85. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523-533.
86. Cobiac L, Nestel PJ, Wing LM, Howe PR. Effects of dietary sodium restriction and fish oil supplements on blood pressure in the elderly. Clin Exp Pharmacol Physiol 1991; 18: 265-268.
87. Chin JP, Dart AM. Therapeutic restoration of endothelial function in hypercholesterolaemic subjects: effect of fish oils. Clin Exp Pharmacol Physiol 1994; 21: 749-755.
88. Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol 1993; 21: 982-989.
89. Goodfellow J, Bellamy MF, Ramsey MW et al. Dietary supplementation with marine omega-3 fatty acids improves systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35: 265-270.
90. Goode GK, Garcia S, Heagerty AM. Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation 1997; 96(9): 2802-2807.
91. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; ii: 433-435.
92. Cartwright IJ, Pockley AG, Galloway JH et al. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985; 55: 267-281.
93. DeCaterina R, Giannessi D, Mazzone A et al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990; 82: 428-438.
94. Force T, Milani R, Hibberd P et al. Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift: analysis of the effects of a combination of aspirin and n-3 fatty acids on the eicosanoid profile. Circulation 1991; 84: 2286-2293.
95. Archer SL. Green D. Chamberlain M et al. Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the coronary artery risk development in young adults (CARDIA) study. Arterioscl Thromb Vascl Biol 1998; 18: 1119-1123.
96. Fumeron F, Brigant L, Ollivier V et al. n-3 polyunsaturated fatty acids raise low-density lipoproteins, high-density lipoprotein 2, and plasminogen-activator inhibitor in healthy young men. Am J Clin Nutr 1991; 54: 118-122.
97. Sanders TAB. Marine oils: metabolic effects and role in human nutrition. Proc Nutr Soc 1993; 52: 457-472.
98. De Catarina R, Cybulsky MI, Clinton SK et al. The omega-3 fatty acids and endothelial leukocyte adhesion molecules. Prostagl Leukotr Ess Fatty Acids 1995; 52: 191-195.
99. Weber C, Erl W, Pietsch A et al. Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 1995; 15: 622-628.
100. Johansen O, Seljeflot I, Hostmark AT, Arnesen H. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1681-1686.
101. Kaminski WE, Jendraschak E, Kiefl R, von Schacky C. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood 1993; 81: 1871-1879.
102. Mantzioris E, Cleland LG, Gibson RA et al. Biochemical effects of a diet containing foods enriched with n-3 fatty acids. Am J Clin Nutr 2000; 72: 42-48.
103. De Caterina R, Basta G. n-3 fatty acids and the inflammatory response-biological background. Eur Heart J 2001; 3(suppl D): D42-D49.
104. Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol 2000; 11: 3-7.
105. Baillie RA, Takada R, Nakamura M, Clarke SD. Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body fat deposition. Prostagl Leukotr Ess Fatty Acids 1999; 60: 351-356.
106. DeLany JP, Blohm F, Truett AA et al. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999; 276: R1172-R1179.
107. Mater MK, Thelen AP, Pan DA, Jump DB. Sterol response element-binding protein 1c (SREBP1c) is involved in the polyunsaturated fatty acid suppression of hepatic S14 gene transcription. J Biol Chem 1999; 274: 32725-32732.
108. Mackness MI, Bhatnagar D, Durrington PN et al. Effect of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr 1994; 48: 859-865.
109. Sirtori CR, Crepaldi G, Manzato E et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis 1998; 137: 419-427.
110. Farmer A, Montori V, Dineen S, Clar C. Fish oil in people with type 2 diabetes mellitus (Cochrane Review). In: Cochrane Library, Issue 1. Oxford: Update Software, 2002.
111. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Therapeut 1998; 79: 205-230.
112. Caslake MJ, Packard CJ, Series JJ et al. Plasma triglyceride and low density lipoprotein metabolism. Eur J Clin Invest 1992; 22: 96-104.
113. Calabresi L, Donati D, Pazzucconi F et al. Omacor in familial combined hyperlipidaemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000; 148: 387-396.
114. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.
115. Frick MH, Elo O, Haapa K et al. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. Helsinki Heart Study. N Engl J Med 1987; 317: 1237-1245.
116. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-418.
117. Criqui MH. Triglycerides and cardiovascular disease: a focus on clinical trials. Eur Heart J 1998; 19(suppl A): A36-A39.
118. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 1998; 141(suppl 1): S57-S62.
119. Sandset PM, Lund H, Norseth J et al. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991; 11: 138-145.
120. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993; 13: 1755-1762.
121. Salvi A, Distefano O, Sleiman I et al. Effects of fish oil on serum lipids and lipoprotein(a) levels in heterozygous familial hypercholesterolemia. Curr Therapeut Res 1993; 53: 717-721.
122. Nordoy A, Bonaa KH, Nilsen H et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoprotein and lipid peroxidation in patients with combined hyperlipidaemia. J Int Med 1998; 243: 163-170.
123. Nakamura N, Hamazaki T, Ohta M et al. Joint effects of HMG-CoA reductase inhibitors and eicosapentanoic acids on serum lipid profile and fatty acid concentrations inpatients with hyperlipdaemia. Int J Clin Lab Res 1999; 29: 22-25.
124. Nordoy A, Bonaa KH, Sandset PM et al. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipaemia in patients with combined hyperlipidaemia. Arteriosclr Thromb Vasc Biol 2000; 20: 259-265.
125. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metabol Cardiovasc Dis 2001; 11: 7-16.
126. Durrington PN, Bhatnagar D, Mackness MI et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85: 544-548.
127. Stein EA, Lane M, Laskarzewski P. Comparisons of statins in hypertriglyceridaemia. Am J Cardiol 1998; 81: 66B-69B.
128. Feussner G. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1994; 5: 59-69.
129. Bilheimer DW, Grundy SM, Brown MS et al. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolaemia heterozygotes. Proc Natl Acad Sci 1983; 80: 4124-4128.
130. Grundy SJ, Bilheimer DW. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolaemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci 1984; 81: 2538-2542.
131. Harris WS, Windsor SL, Caspermeyer JJ. Modification of lipid-related atherosclerosis risk factors by omega-3 fatty acid ethyl esters in hypertriglyceridemic patients. J Nutr Biochem 1993; 4: 706-712.